Matinas Biopharma Hldgs, Inc. (MTNB)

[RealFooFighters]

LNC Remdesivir Update

"First, we very recently received data from the second in vivo study of oral LNC remdesivir in mice infected with SARS-CoV-2. The study.. demonstrated that an oral LNC formulation of remdesivir significantly reduced viral lung titres as early as day two, significantly improved lung congestion scores, and significantly improved COVID-associated weight loss in a well established model of SARS-CoV-2. We are still waiting final histological analyses and will shortly be discussing next steps with the NIAID and Gilead. These data are important for two reasons: first, the therapeutic efficacy against SARS-CoV-2 of an oral formulation of remdesivir itself, and second, the very encouraging early knockdown of lung viral titres, something that might not otherwise be expected with conventional IV remdesivir." (Ferguson)

Jabbour excerpts:

“With Gilead.. they do have and have developed a pro-drug of remdesivir - it’s not remdesivir, to be clear, that they have also studied in pre-clinical models at UNC.

Ours actually is an oral version of remdesivir, which obviously has regulatory advantages as you think about streamlined development pathways, so the enthusiasm is there.

For us, we need the full data set from UNC and NIH. We’re still waiting on the histo. We will reengage with Gilead at that time, although they’ve already seen the data generated to date.

..We certainly are interested in continuing to engage with Gilead and really optimizing the potential remdesivir has as an oral--actual remdesivir as an oral drug, .. We would expect at some point that this data will be published, and that’s something that remains under discussion with Gilead.”

May Update (Slides 13 & 14)
https://d1io3yog0oux5.cloudfront.net/_39593dbf8dddbc5842c6eb613c099aae/matinasbiopharma/db/215/2522/pdf/Matinas+-+Investor+Relations+-+Corporate+Presentation+-+May+2022+FINAL+05.012.22.pdf